Effect of liraglutide on cardiometabolic profile and on bioelectrical impedance analysis in patients with obesity and metabolic syndrome.

Freitas FPC, Rodrigues CEM

Scientific reports11 Aug 2023Cited by 7 (Europe PMC)

PMID37567946PMCIDPMC10421848DOI10.1038/s41598-023-40366-4PepBankPUB-37567946

Summary

Metabolic syndrome (MetS) and obesity represent a public health problem worldwide. Bioelectrical impedance analysis (BIA) is a practical and effective way of evaluating body composition, especially abdominal fat. Liraglutide, a GLP-1 analog, reduces body weight and improves cardiometabolic parameters. In this prospective non-randomized intervention study, we evaluated the effect of 6 months of treatment with liraglutide (n = 57) on the clinical, laboratory and BIA findings of adult sex-stratified patients diagnosed with obesity and MetS, compared to a control group receiving sibutramine (n = 46). The groups were statistically similar with regard to the age of females (p = 0.852) and males (p = 0.657). Almost all anthropometric and BIA variables were higher in the treatment group than in the comparative group (p < 0.05). Abdominal circumference (AC) decreased significantly more in the treatment group. In males, body weight and fat mass also decreased (p < 0.05). Liraglutide treatment was associated with a greater reduction in trunk fat mass (FMT) (p < 0.05). AC and FMT were strongly correlated (rho = 0.531, p < 0.001) in the treatment group. In the multiple regression analysis, liraglutide treatment remained independently associated with FMT. Treatment with liraglutide for 6 months promoted weight loss, improved cardiometabolic and inflammatory parameters and led to a significant reduction in FMT correlated with AC in obese MetS patients of both sexes.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In adults with obesity and metabolic syndrome, abdominal circumference decreased significantly more with 6 months of liraglutide than with sibutramine.
In plain wordsIn adults with obesity and metabolic syndrome, waist size fell more with liraglutide than with sibutramine.
Peptide
Liraglutide
Outcome
DecreaseAbdominal circumference
Study
n = 103
Comparator
Sibutramine
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Abdominal circumference (AC) decreased significantly more in the treatment group.
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective non-randomized intervention study, we evaluated the effect of 6 months of treatment with liraglutide (n = 57) on the clinical, laboratory and BIA findings of adult sex-stratified patients diagnosed with obesity and MetS, compared to a control group receiving sibutramine (n = 46).
Show in the study text Report a problemFND-3756794601
02HumanNon-randomized trialEfficacy outcome
In adults with obesity and metabolic syndrome, liraglutide treatment was associated with a greater reduction in trunk fat mass than the sibutramine control.
In plain wordsIn adults with obesity and metabolic syndrome, liraglutide was linked to a larger loss of fat around the trunk than sibutramine.
Peptide
Liraglutide
Outcome
DecreaseTrunk fat mass (FMT)
Study
n = 103
Comparator
Sibutramine
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Liraglutide treatment was associated with a greater reduction in trunk fat mass (FMT) (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective non-randomized intervention study, we evaluated the effect of 6 months of treatment with liraglutide (n = 57) on the clinical, laboratory and BIA findings of adult sex-stratified patients diagnosed with obesity and MetS, compared to a control group receiving sibutramine (n = 46).
Show in the study text Report a problemFND-3756794604
03HumanNon-randomized trialEfficacy outcome
In males with obesity and metabolic syndrome, body weight decreased with 6 months of liraglutide treatment.
In plain wordsIn men with obesity and metabolic syndrome, body weight fell with liraglutide.
Peptide
Liraglutide
Outcome
DecreaseBody weight in males
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
In males, body weight and fat mass also decreased (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective non-randomized intervention study, we evaluated the effect of 6 months of treatment with liraglutide (n = 57) on the clinical, laboratory and BIA findings of adult sex-stratified patients diagnosed with obesity and MetS, compared to a control group receiving sibutramine (n = 46).
Show in the study text Report a problemFND-3756794602
04HumanNon-randomized trialEfficacy outcome
In males with obesity and metabolic syndrome, fat mass decreased with 6 months of liraglutide treatment.
In plain wordsIn men with obesity and metabolic syndrome, fat mass fell with liraglutide.
Peptide
Liraglutide
Outcome
DecreaseFat mass in males
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
In males, body weight and fat mass also decreased (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective non-randomized intervention study, we evaluated the effect of 6 months of treatment with liraglutide (n = 57) on the clinical, laboratory and BIA findings of adult sex-stratified patients diagnosed with obesity and MetS, compared to a control group receiving sibutramine (n = 46).
Show in the study text Report a problemFND-3756794603
05HumanNon-randomized trialOther
In adults with obesity and metabolic syndrome treated with liraglutide, abdominal circumference and trunk fat mass were strongly correlated.
In plain wordsIn adults with obesity and metabolic syndrome treated with liraglutide, waist size and trunk fat were closely linked.
Peptide
Liraglutide
Outcome
Not applicableCorrelation of abdominal circumference with trunk fat mass
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
correlation coefficient (rho)
0.531 rho
treatment group
Source sentences
Summary
AC and FMT were strongly correlated (rho = 0.531, p < 0.001) in the treatment group.
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective non-randomized intervention study, we evaluated the effect of 6 months of treatment with liraglutide (n = 57) on the clinical, laboratory and BIA findings of adult sex-stratified patients diagnosed with obesity and MetS, compared to a control group receiving sibutramine (n = 46).
Show in the study text Report a problemFND-3756794605
06HumanNon-randomized trialOther
In adults with obesity and metabolic syndrome, liraglutide treatment remained independently associated with trunk fat mass in multiple regression.
In plain wordsIn adults with obesity and metabolic syndrome, liraglutide treatment was linked to trunk fat mass even after adjusting for other factors.
Peptide
Liraglutide
Outcome
Direction not reportedIndependent association of liraglutide treatment with trunk fat mass
Study
n: not reported in source
Comparator
Sibutramine
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
In the multiple regression analysis, liraglutide treatment remained independently associated with FMT.
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective non-randomized intervention study, we evaluated the effect of 6 months of treatment with liraglutide (n = 57) on the clinical, laboratory and BIA findings of adult sex-stratified patients diagnosed with obesity and MetS, compared to a control group receiving sibutramine (n = 46).
Show in the study text Report a problemFND-3756794606

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.